An Open Label, Proof of Concept Study to Assess the Safety, PK and Explore Efficacy of OPRX-106 in Patients With Active Mild to Moderate Ulcerative Colitis

Trial Profile

An Open Label, Proof of Concept Study to Assess the Safety, PK and Explore Efficacy of OPRX-106 in Patients With Active Mild to Moderate Ulcerative Colitis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Jan 2018

At a glance

  • Drugs PRX 106 (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions; Pharmacokinetics; Proof of concept
  • Sponsors Protalix Biotherapeutics
  • Most Recent Events

    • 02 Jan 2018 According to a Protalix Biotherapeutics media release, the Company expects to report full results from this study by the end of the first quarter of 2018.
    • 02 Jan 2018 Interim results (n=14) published in a Protalix Biotherapeutics media release.
    • 29 Nov 2017 Status changed from recruiting to active, no longer recruiting, according to a Protalix BioTherapeutics media trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top